Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 1656

Next Previous
Drug Profile

AZD 1656

Alternative Names: AZD-1656

Latest Information Update: 19 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca
  • Developer AstraZeneca; ClinConnect; Conduit Pharmaceuticals
  • Class Anti-inflammatories; Antihyperglycaemics; Azetidines; Benzamides; Ethers; Ketones; Methyl ethers; Obesity therapies; Phenyl ethers; Pyrazines; Small molecules; Urologics
  • Mechanism of Action Glucokinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Lymphomatous thyroiditis; Preterm labour; Renal failure; Uveitis
  • Preclinical Anti-neutrophil cytoplasmic antibody-associated vasculitis; Systemic lupus erythematosus
  • Discontinued Type 1 diabetes mellitus; Type 2 diabetes mellitus

Most Recent Events

  • 09 May 2025 Conduit Pharmaceuticals has patent protection for AZD 1656 in South Korea
  • 10 Apr 2025 Conduit Pharmaceuticals plans a phase-II trial for Systemic lupus erythematosus, and Anti-neutrophil-cytoplasmic-antibody-associated-vasculitis in the year 2025 (Oral),
  • 31 Mar 2025 Conduit Pharmaceuticals has patent protection for AZD 1656 in USA

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top